

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M.10449 - KIA / ALMAVIVA**

## **SECTION 1.2**

### **Description of the concentration**

On 25 October 2021, the European Commission received a notification for a proposed concentration pursuant to Article 4 of Council Regulation No. 139/2004, by which a special purpose vehicle ultimately controlled by Wren House Infrastructure LP, incorporated in England, itself exclusively controlled by the Kuwait Investment Authority, an autonomous government agency of the State of Kuwait, would acquire the exclusive control of Almaziva Capital S.A.S, incorporated in France.

The Proposed Transaction entails the change of exclusive control exercised by Ambroise Luxco, an investment vehicle controlled by Antin, over Almaziva Capital S.A.S. to sole control by Wren House Infrastructure LP, itself exclusively controlled by the Kuwait Investment Authority, as defined in Article 3(1) of Regulation No 139/2004.

The Proposed Transaction will be implemented through a purchase of all the shares of Almaziva Capital S.A.S.

Wren House Infrastructure LP is the captive direct infrastructure investment vehicle for the Kuwait Investment Authority. The Kuwait Investment Authority manages the sovereign wealth funds of the State of Kuwait as a global investor, with investments in all main geographical areas (including the Americas, Europe and Asia-Pacific) and asset classes (including real estate, private and public equity, fixed income and alternative investment markets across the globe).

Almaziva Capital S.A.S. is the head of the Almaziva Group, active in the health sector, and in particular operating diagnostics and hospital care services. Almaziva Group is active in France, and has a limited activity in Canada.